- 作者: Tsung-Chih Tsai, Yi-Syuan Fang, Yu-Chieh Hung, Ling-Chien Hung & Kuei-Sen Hsu
- 作者服務機構: 1.Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Rd., Tainan, 70101, Taiwan 2.Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan
- 中文摘要:
- 英文摘要:
Background: With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and
immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efcacy.
Methods: We report an mRNA-based vaccine using an engineered “hybrid” receptor binding domain (RBD) that
contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants.
Results: A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high
titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid
vaccine generated strong Omicron-specifc neutralizing antibodies as well as low but signifcant titers against other
VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild
type and all VOCs.
Conclusions: These results demonstrate that inclusion of diferent antigenic mutations from various SARS-CoV-2
variants is a feasible approach to develop cross-protective vaccines. - 中文關鍵字:
- 英文關鍵字: Omicron vaccine, mRNA vaccine, SARS-CoV-2, COVID-19, Variants of concern, Hybrid vaccine, Booster dose, Next generation vaccine, Cross-protectivity